There is no publicly available discount card or savings program specifically for Velphoro mentioned in the provided information.
Who makes Velphoro?
Velphoro is manufactured by Akebia Therapeutics [1].
What is Velphoro used for?
Velphoro is a ferric citrate product used to treat hyperphosphatemia in adult patients with chronic kidney disease (CKD) on dialysis [1]. Hyperphosphatemia is a condition characterized by abnormally high levels of phosphate in the blood, which can lead to serious health complications for dialysis patients.
How does Velphoro work?
Velphoro functions as a phosphate binder [1]. When taken with meals, it binds to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. This mechanism helps to lower serum phosphate levels.
How is Velphoro taken?
Velphoro is administered orally [1]. Patients typically take it during meals or shortly after. The dosage is determined by a healthcare provider based on individual patient needs and serum phosphate levels.
What are the side effects of Velphoro?
Common side effects associated with Velphoro include diarrhea, nausea, vomiting, and constipation [1]. Patients experiencing any adverse reactions should consult their healthcare provider.
How does Velphoro compare to other phosphate binders?
Velphoro is a ferric citrate-based binder [1]. Other phosphate binders include calcium-based binders (like calcium acetate and calcium carbonate) and non-calcium, non-aluminum binders (like sevelamer and lanthanum carbonate). Ferric citrate, as found in Velphoro, offers an alternative mechanism for phosphate binding, and its efficacy and safety profile are evaluated against these other classes of drugs.
What is the patent status of Velphoro?
Information regarding specific patents and their expiration dates for Velphoro is not provided in the given text. For detailed patent information, resources like DrugPatentWatch.com may offer further insights [2].